Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Phase 3 Completed 426 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.

Timeline

Start: 2007-10-09
Primary completion: 2011-03-16
Completion: 2011-03-16

Publications

Results Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, Kaufman KD, Goldstein BJ. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013 May;36(5):1067-73. doi: 10.2337/dc12-1365. Epub 2012 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Glipizide	Small molecule	2.5 mg	Oral
Comparator	Glipizide	Small molecule	20 mg	Oral
Subject	Sitagliptin	Small molecule	25 mg	Oral
Subject	Sitagliptin	Small molecule	50 mg	Oral

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Summary

Timeline

Publications

Drugs

Indications